# Processa Pharmaceuticals, Inc.: financial statements, quarterly PCSA · Nasdaq · CIK 1533743 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/pcsa.md) · [Financials](/companies/pcsa/financials.md) · [Filings](/companies/pcsa/filings.md) · [Insiders](/companies/pcsa/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pcsa/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0 d](/filings/0001493152-23-040472.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross profit | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Research and development | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Selling, general and administrative | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating income | $k | [(2,168)](/filings/0001493152-24-043058.md) | [(2,469) d](/filings/0001641172-25-000070.md) | [(2,810)](/filings/0001641172-25-009252.md) | [(3,082)](/filings/0001493152-25-011685.md) | [(3,425)](/filings/0001493152-25-021069.md) | [(2,735) d](/filings/0001493152-26-011204.md) | [(2,847)](/filings/0001493152-26-021721.md) | [(3,951)](/filings/0001493152-26-038334.md) | [(3,489)](/filings/0001493152-25-021069.md) | [(3,702) d](/filings/0001493152-26-011204.md) | [(3,331)](/filings/0001493152-26-021721.md) | [(2,336)](/filings/0001493152-26-038334.md) | | Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net income | $k | [(2,082)](/filings/0001493152-24-043058.md) | [(2,405) d](/filings/0001641172-25-000070.md) | [(2,726)](/filings/0001493152-25-021069.md) | [(3,010)](/filings/0001493152-25-021069.md) | [(3,385)](/filings/0001493152-25-021069.md) | [(2,729) d](/filings/0001493152-26-011204.md) | [(2,834)](/filings/0001493152-26-038334.md) | [(3,934)](/filings/0001493152-26-038334.md) | [(3,437)](/filings/0001493152-25-021069.md) | [(3,359) d](/filings/0001493152-26-011204.md) | [(3,377)](/filings/0001493152-26-038334.md) | [(3,265)](/filings/0001493152-26-038334.md) | | Diluted EPS | $ per share | [(1.54)](/filings/0001493152-24-043058.md) | not reported | [(1.11)](/filings/0001641172-25-009252.md) | [(1.01)](/filings/0001493152-25-011685.md) | [(1.03)](/filings/0001493152-25-021069.md) | not reported | [(7.58)](/filings/0001493152-26-021721.md) | [(6.26)](/filings/0001493152-26-038334.md) | [(0.07)](/filings/0001493152-25-021069.md) | not reported | [(1.29)](/filings/0001493152-26-021721.md) | [(1.19)](/filings/0001493152-26-038334.md) | | Basic EPS | $ per share | [(1.54)](/filings/0001493152-24-043058.md) | not reported | [(1.11)](/filings/0001641172-25-009252.md) | [(1.01)](/filings/0001493152-25-011685.md) | [(1.03)](/filings/0001493152-25-021069.md) | not reported | [(7.58)](/filings/0001493152-26-021721.md) | [(6.26)](/filings/0001493152-26-038334.md) | [(0.07)](/filings/0001493152-25-021069.md) | not reported | [(1.29)](/filings/0001493152-26-021721.md) | [(1.19)](/filings/0001493152-26-038334.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: not reported - Gross profit: not reported - Research and development: not reported - Selling, general and administrative: not reported - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: not reported - Income tax: not reported - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $k | [6,861](/filings/0001493152-23-040472.md) | [4,706](/filings/0001641172-25-000070.md) | [8,920](/filings/0001493152-24-018648.md) | [5,571](/filings/0001493152-24-031622.md) | [2,891](/filings/0001493152-24-043058.md) | [1,191](/filings/0001493152-26-011204.md) | [2,897](/filings/0001641172-25-009252.md) | [6,937](/filings/0001493152-25-011685.md) | [6,308](/filings/0001493152-25-021069.md) | [5,537](/filings/0001493152-26-038334.md) | [1,691](/filings/0001493152-26-021721.md) | [196](/filings/0001493152-26-038334.md) | | Current assets | $k | [7,907](/filings/0001493152-23-040472.md) | [5,632](/filings/0001641172-25-000070.md) | [9,800](/filings/0001493152-24-018648.md) | [7,478](/filings/0001493152-24-031622.md) | [4,838](/filings/0001493152-24-043058.md) | [1,879](/filings/0001493152-26-011204.md) | [3,758](/filings/0001641172-25-009252.md) | [7,154](/filings/0001493152-25-011685.md) | [6,587](/filings/0001493152-25-021069.md) | [5,671](/filings/0001493152-26-038334.md) | [1,938](/filings/0001493152-26-021721.md) | [2,066](/filings/0001493152-26-038334.md) | | Total assets | $k | [8,083](/filings/0001493152-23-040472.md) | [5,787](/filings/0001641172-25-000070.md) | [9,945](/filings/0001493152-24-018648.md) | [7,601](/filings/0001493152-24-031622.md) | [4,942](/filings/0001493152-24-043058.md) | [3,229](/filings/0001493152-26-011204.md) | [4,810](/filings/0001641172-25-009252.md) | [8,182](/filings/0001493152-25-011685.md) | [7,585](/filings/0001493152-25-021069.md) | [7,814](/filings/0001493152-26-038334.md) | [4,521](/filings/0001493152-26-021721.md) | [2,070](/filings/0001493152-26-038334.md) | | Current liabilities | $k | [826](/filings/0001493152-23-040472.md) | [731](/filings/0001641172-25-000070.md) | [1,011](/filings/0001493152-24-018648.md) | [1,552](/filings/0001493152-24-031622.md) | [1,219](/filings/0001493152-24-043058.md) | [1,533](/filings/0001493152-26-011204.md) | [1,283](/filings/0001641172-25-009252.md) | [2,075](/filings/0001493152-25-011685.md) | [1,751](/filings/0001493152-25-021069.md) | [2,236](/filings/0001493152-26-038334.md) | [1,980](/filings/0001493152-26-021721.md) | [2,387](/filings/0001493152-26-038334.md) | | Total liabilities | $k | [915](/filings/0001493152-23-040472.md) | [797](/filings/0001641172-25-000070.md) | [1,061](/filings/0001493152-24-018648.md) | [1,577](/filings/0001493152-24-031622.md) | [1,221](/filings/0001493152-24-043058.md) | [1,533](/filings/0001493152-26-011204.md) | [1,283](/filings/0001641172-25-009252.md) | [2,075](/filings/0001493152-25-011685.md) | [1,751](/filings/0001493152-25-021069.md) | [2,236](/filings/0001493152-26-038334.md) | [1,980](/filings/0001493152-26-021721.md) | [2,387](/filings/0001493152-26-038334.md) | | Long-term debt | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Current portion of debt | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $k | [7,168](/filings/0001493152-24-043058.md) | [4,989](/filings/0001493152-26-011204.md) | [8,883](/filings/0001493152-25-021069.md) | [6,024](/filings/0001493152-25-021069.md) | [3,721](/filings/0001493152-25-021069.md) | [1,696](/filings/0001493152-26-038334.md) | [3,527](/filings/0001493152-26-038334.md) | [6,107](/filings/0001493152-26-038334.md) | [5,834](/filings/0001493152-25-021069.md) | [5,577](/filings/0001493152-26-038334.md) | [2,541](/filings/0001493152-26-038334.md) | [(317)](/filings/0001493152-26-038334.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: not reported - Current portion of debt: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $k | [(1,761) d](/filings/0001493152-24-043058.md) | [(2,124) d](/filings/0001641172-25-000070.md) | [(2,049)](/filings/0001641172-25-009252.md) | [(3,346) d](/filings/0001493152-25-011685.md) | [(3,603) d](/filings/0001493152-25-021069.md) | [(2,248) d](/filings/0001493152-26-011204.md) | [(2,730)](/filings/0001493152-26-021721.md) | [(2,270) d](/filings/0001493152-26-038334.md) | [(3,484) d](/filings/0001493152-25-021069.md) | [(2,901) d](/filings/0001493152-26-011204.md) | [(3,591)](/filings/0001493152-26-021721.md) | [(1,996) d](/filings/0001493152-26-038334.md) | | Capital expenditure | $k | not reported | [0.0 d](/filings/0001641172-25-000070.md) | not reported | not reported | not reported | [0.0 d](/filings/0001641172-25-000070.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [16.2](/filings/0001493152-23-040472.md) | [1.1](/filings/0001493152-24-018648.md) | [1.3](/filings/0001493152-24-031622.md) | [1.4](/filings/0001493152-24-043058.md) | [2.5](/filings/0001641172-25-009252.md) | [3.0](/filings/0001493152-25-011685.md) | [3.3](/filings/0001493152-25-021069.md) | [0.4](/filings/0001493152-26-021721.md) | [0.6](/filings/0001493152-26-038334.md) | [47.5](/filings/0001493152-25-021069.md) | [2.6](/filings/0001493152-26-021721.md) | [2.8](/filings/0001493152-26-038334.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 2,793,386 at 2026-08-07, from the cover of the [10-Q filed 2026-08-14](/filings/0001493152-26-038334.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.